Idag den 14 december 2020, hölls årsstämma i ODI Pharma AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July – September 2020. The report is available...

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI”) hereby publish the annual report of the fiscal year...

ODI Pharma AB (“ODI” or “the Company”), through research carried out by its subsidiary ODI Pharma Schweiz AG, announces that the Company...

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In...

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma måndagen den 14 december 2020 kl. 10.00 på Engelbrektsgatan...

Stockholm, Sweden and Leamington, Ontario – November 2nd, 2020 – ODI Pharma AB (“ODI”, ISIN SE0013409760) today announced that, despite...

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its year-end report for the period July 2019 – June 2020. The report is available...

ODI Pharma AB (“ODI” or “the Company”) gives an update regarding that a MAR label was missing in the quarterly report published 28th of...

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its interim report for the period July 2019 – March 2020. The report is available...

ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Board of Directors does not see any impact on the Company’s mid- and...

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its half-yearly report for the period October – December 2019. The report is...

ODI Pharma AB (“ODI Pharma” or “the Company”) hereby announce that Aphria Inc. (“Aphria”), the Company’s supplier of medical cannabis,...

Stockholm, 20.01.2020. As communicated earlier today, ODI Pharma AB's (“ODI Pharma” or “Company”) recently completed new share issue has...

Stockholm, 20.01.2020. ODI Pharma AB's ("ODI Pharma" or "Company") recently completed new share issue was significantly oversubscribed...

The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was...

ODI Pharma AB (“ODI Pharma” or “the Company”), a medical cannabis finished product producer, today announces that the Company has been...

Zug/Switzerland, August 2nd, 2019 - The board of ODI Pharma Schweiz AG announces that its operations will be consolidated shortly under a...